As gain-of-function mutations of LRRK2 are strongly associated with hereditary and sporadic forms of Parkinson disease, LRRK2 kinase inhibition has been pursued as a potential therapeutic strategy38,39. Here, LRRK2 is linked to Parkinson disease.